Regeneron Gains 13.5% Year to date: How to Play the Stock?

Shares of Regeneron Pharmaceuticals, Inc. (REGN) have gained 13.5% in the year so far against the industry’s decline of 2.8%.The stock has outperformed the sector during this timeframe but underperformed the S&P 500 Index.REGN Outperforms Industry & SectorImage Source: Zacks Investment ResearchRegeneron’s efforts to diversify its portfolio have impressed its investors, even as lead drug Eylea faces challenges.Regeneron’s EYLEA HD Stabilizes Ophthalmology UnitEylea is an anti-vascular endothelial growth fact ...